Alpha-9 Oncology received $175 Million in Series C financing round

Alpha-9 Oncology Inc has announced that it has received $175 Million from Lightspeed Venture Partners and Ascenta Capital in Series C round including from existing investors and other top-tier new investor.

The company got the backing of top tier syndicate of investors which includes big names like General Catalyst, Delos Capital, a16z Bio + Health, Janus Henderson Investors, RA Capital Management, Digitalis Ventures, Lumira Ventures and a healthcare fund managed by abrdn Inc.

Alpha-9 Oncology which is a clinical stage company and is in the development of radiopharmaceuticals has announced that this funding will be used for finding the solutions of those patients who are suffering from multiple tumors and whose needs go unmet due to any reasons. The company will use this funding toward clinical studies of targeted radiopharmaceuticals and will spend significant amount for the isotope supply partnerships and in the expansion of its manufacturing.

David Hirsch is the CEO of Alpha-9 Theranostics and he has said that the company has a robust infrastructure and a deep pipeline and is one of the market leader in radiopharmaceutical sector and it is working day and night to improve the life of people suffering from tumors. He also said the company is working on state of the art solutions that includes multiple radiopharmaceuticals with best in class potential.